A faster, cheaper cell therapy is about to be tested in humans

Plus: GLP-1s associated with lower risk of 10 obesity-related cancers

July 9, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | A faster, simpler, cheaper cancer cell therapy is about to be tested in humans CAR-Ts can cure some blood cancers but are difficult to produce. A new study will test if a simple infusion could make it available for all. By Jason Mast STAT+ | GLP-1s associated with lower risk of 10 obesity-related cancers, study shows The retrospective study, published Friday, found that GLP-1s better mitigated the risk of 10 obesity-associated cancers than diabetes drug alternatives. By Rohan Rajeev STAT+ | Eli Lilly to acquire Morphic for $3.2 billion Lilly, flush with cash from sales of its blockbuster GLP-1-based treatments, has struck a number of deals and partnerships last year and this year. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser